Limits of Dideoxysequencing in the Detection of Somatic Mutations in Gastrointestinal Stromal Tumors

1. Lodish H, Berk A, Matsudaira P et al. Molecular Cell Biology. New York: H. Freeman, 2007.Search in Google Scholar

2. Hostein I, Faur N, Primois C et al. BRAF mutations status in gastrointestinal stromal tumors. Am. J Clin Pathol 2010; 1 (133): 141-148.10.1309/AJCPPCKGA2QGBJ1R20023270Search in Google Scholar

3. Su Z, Dias-Santagata D, Duke M et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 2011; 13 (1): 74-84.10.1016/j.jmoldx.2010.11.010307055821227397Search in Google Scholar

4. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology 2006; 48 (1): 83-96.10.1111/j.1365-2559.2005.02291.x16359540Search in Google Scholar

5. Agaram NP, Wong GC, Guo T et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008; 47 (10): 853-9.10.1002/gcc.20589290287418615679Search in Google Scholar

6. Agaimy A, Terracciano LM, Dirnhofer S et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 2009; 62 (7): 613-6.10.1136/jcp.2009.06455019561230Search in Google Scholar

7. Rajagopalan H, Bardelli A, Lengauer C et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418 (6901): 934.10.1038/418934a12198537Search in Google Scholar

8. Singer G, Oldt R, Cohen Y et al. Mutations in BRAF and KRAS charac terize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95 (6): 484–6.10.1093/jnci/95.6.48412644542Search in Google Scholar

9. Minarik G, Plank L, Lasabova Z et al. Spectrum of mutations in gastrointestinal stromal tumor patients-apopulation-based study from Slovakia. APMIS 2013; 121 (6): 539-548.10.1111/apm.1201923106360Search in Google Scholar

10. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8 (3): 161-173.10.1677/erc.0.008016111566607Search in Google Scholar

11. Liu J, Huang S, Sun M et al. An improved allele-specific PCR primer design method for SNP marker analysis and its application. Plan Methods 2012; 8 (34).10.1186/1746-4811-8-34349571122920499Search in Google Scholar

12. Kang HY, Hwang JY, Kim SH et al. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica 2006; 91 (5): 659-662.Search in Google Scholar

13. Krieken Van JH, Jung A, Kirchner T et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008; 5 (453): 417-431.10.1007/s00428-008-0665-y18802721Search in Google Scholar